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Abstract: Background
The DAMOCLES project established a widely used Data Monitoring Committee (DMC)
Charter for Randomised Controlled Trials (RCTs). Typically, within the UK, the DMC is
advisory and recommends to another executive body; the Trial Steering Committee
(TSC). Despite the executive role of the TSC, the CONSORT statement doesn't
explicitly require reporting of TSC activity, although is included as an example of good
reporting. A lack of guidance on TSC reporting can impact transparency of trial
oversight, ultimately leading to a misunderstanding regarding role and subsequently
further variation in practice. This review aimed to establish reporting practice of TSC
involvement in RCTs, and thus make recommendations for reporting.
Methods
A cohort examination identifying reporting practice was undertaken. The cohort
comprised RCTs published in three leading medical journals (British Medical Journal,
Lancet and New England Journal of Medicine) within six months in 2012 and the full
HTA Monograph series.  Details of TSC constitution and impact were extracted from
main publications and published supplements.
Results
Of 415 publications, 264 were eligible. These were typical in terms of trial design.
Variations in reporting between journals and monographs was notable. TSC presence
was identified in approximately half of trials (n=144), of which 109 worked alongside a
DMC in 109 of these. No publications justified not convening a TSC.  When reported,
the role of the committee and examples of impact in design, conduct and analysis were
summarised.
Conclusions
We present the first review of reporting TSC activity in the published literature. An
absence of reporting standards with regards to TSC constitution, activity and impact on
trial conduct was identified which can influence transparency of reporting trial
oversight. Consistent reporting is vital for the benefits and impact of the TSC role to be
understood to support adoption of this oversight structure and reduce global variations
in practice.
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 30 
ABSTRACT 31 
Background 32 
The DAMOCLES project established a widely used Data Monitoring Committee (DMC) Charter for Randomised 33 
Controlled Trials (RCTs). Typically, within the UK, the DMC is advisory and recommends to another executive 34 
body; the Trial Steering Committee (TSC). Despite the executive role of the TSC, the CONSORT statement 35 
doesn’t explicitly require reporting of TSC activity, although is included as an example of good reporting. A lack 36 
of guidance on TSC reporting can impact transparency of trial oversight, ultimately leading to a 37 
misunderstanding regarding role and subsequently further variation in practice. This review aimed to establish 38 
reporting practice of TSC involvement in RCTs, and thus make recommendations for reporting. 39 
 40 
Methods 41 
A cohort examination identifying reporting practice was undertaken. The cohort comprised RCTs published in 42 
three leading medical journals (British Medical Journal, Lancet and New England Journal of Medicine) within 43 
six months in 2012 and the full HTA Monograph series.  Details of TSC constitution and impact were extracted 44 
from main publications and published supplements.  45 
 46 
Results 47 
Of 415 publications, 264 were eligible. These were typical in terms of trial design. Variations in reporting 48 
between journals and monographs was notable. TSC presence was identified in approximately half of trials 49 
(n=144), of which 109 worked alongside a DMC in 109 of these. No publications justified not convening a TSC.  50 
When reported, the role of the committee and examples of impact in design, conduct and analysis were 51 
summarised. 52 
 53 
Conclusions 54 
We present the first review of reporting TSC activity in the published literature. An absence of reporting 55 
standards with regards to TSC constitution, activity and impact on trial conduct was identified which can 56 
influence transparency of reporting trial oversight. Consistent reporting is vital for the benefits and impact of 57 
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the TSC role to be understood to support adoption of this oversight structure and reduce global variations in 58 
practice. 59 
Trial registration 60 
Not applicable, not a clinical trial. 61 
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 116 
 117 
BACKGROUND 118 
The DAMOCLES project [1] established a Data Monitoring Committee Charter [2] which has been widely used 119 
for randomised controlled trials since 2005. As established within DAMOCLES, the Data Monitoring Committee 120 
(DMC) is typically advisory and makes recommendations to another executive body; considered the Trial 121 
Steering Committee (TSC). Currently however, no evidence-based Charter exists for TSCs to establish their role 122 
and functionality in RCTs. 123 
 124 
The MRC Guidelines for Good Clinical Practice (1998) defined a three committee oversight structure: the day-125 
to-day Trial Management Group, the DMC and the executive TSC [3]. This document provided guidance and a 126 
suggested terms of reference for TSCs which has been widely adopted within the UK [4]. However, a need for 127 
redevelopment and expansion of these guidelines has been identified [4, 5]. This may have led to these 128 
guidelines recently being withdrawn, and subsequently revised, with limited changes mainly concerning 129 
responsibilities to funder. The need for the  further building the need for the development of expanded universal 130 
guidelines remains [3, https://www.mrc.ac.uk/documents/pdf/guidelines-for-management-of-global-health-131 
trials/].  132 
 133 
Both DAMOCLES [1] and the CONSORT statement [6], an evidence-based minimum set of recommendations for 134 
reporting randomized trials, recommend that trial reports should include information about interim analyses 135 
and the data monitoring process. The purpose of CONSORT is to facilitate the complete and transparent 136 
reporting of trials and as such has been widely adopted by journals to aid critical appraisal and interpretation. 137 
However, there is an absence of content focusing on the clinical trial oversight structure and responsibilities for 138 
decision making. While reporting of DMC activity is included within CONSORT as part of reporting interim 139 
analyses, and DAMOCLES suggests reporting DMC membership, the reporting of TSC activities is not covered.  140 
 141 
The objective of this cohort examination was to establish current practice of reporting of TSC involvement in 142 
RCTs, to recommend reporting standards for TSC activity and to identify impact on trial conduct.  143 
 144 
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METHODS 145 
Search strategy 146 
EJC searched publications within a six month period (1st July 2012 to 31st December 2012) from four sources. 147 
Three top general medical journals (the British Medical Journal (BMJ), the Lancet and the New England Journal 148 
of Medicine (NEJM)) and within the full UK National Institute for Health Research Health Technology 149 
Assessment (NIHR HTA) Monograph series. Journals were selected that are known for endorsing high 150 
standards of reporting when publishing RCTs. The NIHR HTA Monograph Series, a peer-reviewed open access 151 
journal that publishes full details of a single study funded by the NIHR HTA funding stream. NIHR HTA is a 152 
major UK funding body which supports policy makers such as the National Institute for Health and Care 153 
Excellence, the National Screening Committee and the Department of Health [7]. The full NIHR HTA 154 
Monograph series was searched as opposed to those published within the set timeframe because this series 155 
has a suggested word count of 50 000 and so enables more details of the work to be included when compared 156 
to a typical peer reviewed journal and so were considered more likely to provide a comprehensive description 157 
of TSC remit and function. Therefore, when summarising examples of reporting, results from journals and 158 
monographs are reported separately. 159 
 160 
Published RCTs were identified by searching of titles, abstracts and keywords of primary research papers 161 
published within the timeframe using the search term random*. When eligibility was unclear a second reviewer 162 
(CG) was consulted.  163 
 164 
Inclusion criteria 165 
We included all RCTs publishing main trial results. Articles presenting results of: secondary analyses; preliminary 166 
analyses; and additional reports of published RCTs, for example results of long term follow up, were excluded. 167 
 168 
Data extraction and analysis 169 
A data extraction form was designed and piloted by EJC and CG. Data was extracted from all published materials 170 
(main trial report and supplementary material when applicable). EJC extracted data on trial design, trial stopping 171 
and oversight committee reporting (see Box 1) and entered into an MS Access database. BA independently 172 
extracted data from a random 10%, stratified by TSC reporting and source.  173 
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 174 
Quantitative items were analysed using descriptive statistics. Standard statistical software was used throughout 175 
(Statistical Analysis Software (SAS 9.1.3; SAS Institute Inc., Cary, NC, USA). Text extracts from articles were 176 
examined using NVivo qualitative data analysis software (QSR International Pty Ltd. Version 10, 2012). EJC and 177 
CG identified themes within text items which were used to contextualise and illuminate quantitative results. 178 
Extracts are denoted by […] and [words] denoted addition of words or replaced words to aid understanding. 179 
Each paper was mapped to a unique project identification number; details of this mapping are given in 180 
Supplementary Table 1. Due to differences in focus of paper between journal manuscripts and the monograph 181 
series, results are presented split by source and, where applicable, split into sections appropriate for the content. 182 
 183 
RESULTS 184 
Eligible cohort and demographics 185 
Electronic jJournals were searched in May 2013. The search returned 415 hits, of which 264 (63.6%) were 186 
deemed eligible (127 HTA; 16 BMJ; 66 Lancet; 55 NEJM). Figure 1 provides Further further details of this 187 
process are displayed in Figure 1. Funders of trialsTrial funders were geographically distributed with the 188 
majority of funders being of UK (n=161, 61.0%) or USA (n=50, 18.9%) origin. Typically trials within this cohort 189 
were parallel (n=233, 88.3%), two-armed, (n=185, 70.1%) with a pharmaceutical intervention (n=132, 50.0%) 190 
and was blinded (n=162, 61.4%). Patients were individually randomised (n=237, 90.5%) within the secondary 191 
and/or tertiary setting (n=128, 48.5%). Other key design features and characteristics, overall and split by 192 
source, are summarised in Table 1. 193 
 194 
Variations in published material 195 
Due to variations in publishing requirements, differences were anticipated between monographs and journals. 196 
However there were clear differences between sources, Key journals were restricted by word count though 197 
supplementary documents were often published. While all three journals encouraged protocol and 198 
supplementary appendices, this appeared to be endorsed by the NEJM only. Further details of published 199 
documents are provided in Table 2.  200 
 201 
Trial oversight committees 202 
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Table 3 describes the level of TSC and DMC reporting split by publication source.  203 
 204 
Publications reporting neither a TSC nor DMC (71/264, 26.9%) varied by source from 7% (NEJM, 4/55) to 63% 205 
(BMJ, 10/16). Only the NEJM and HTA publications justified not having a DMC. NEJM publications justifying no 206 
DMC (n=2) gave reason in the published protocol as a supplement stating the DMC was not applicable [NEJM16] 207 
and: 208 
“A data monitoring committee for efficacy is not required for this study. Data safety monitoring will be 209 
conducted on an ongoing basis as detailed in the Safety Review Plan.” [NEJM44] 210 
 211 
All HTA publications justifying not having a DMC (n=3) gave reasons: the trial examined routine therapies 212 
[HTA67]; no interim analysis were planned [HTA83] and the trial not involving a medicinal product [HTA109].:  213 
“Since this trial involves the use of a commonly available domestic water softening unit (and does not involve a 214 
medicinal product) we do not anticipate the need for a Data Monitoring Committee.” [HTA109] 215 
 216 
Although Of the 120 trials did not explicitly reporting use of a TSC, none justifiedcations were provided for its 217 
absence. 218 
 219 
Aside from trials with cellular or gene therapy interventions of which there were few, TSCs were consistently 220 
reported regardless of intervention type, from 48% of psychological or behavioural intervention trials with a 221 
psychological or behavioural intervention (14/29) to 79% physical intervention of trials with a physical? 222 
intervention (11/14). DMCs were reported less frequently, from 23% in resources and infrastructure trials with 223 
a resources and infrastructure intervention (5/22) to 73% in pharmaceutical interventionin trials with a 224 
pharmaceutical intervention (97/132) or medical device trials (19/26). Trials with neither committee reported 225 
most commonly involved had a complimentary intervention (3/6, 50%) orand psychological and behavioural 226 
(13/29, 45%). Further details are provided in Tables 4. 227 
 228 
Name of TSC 229 
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Trial Steering Committee was the most common TSC name (61/144, 42%). Other common names variants were 230 
steering committee (42/144, 29%); steering group (14/144, 10%) and executive committee (10/144, 7%). Table 231 
5 shows other variations. 232 
 233 
TSCs 234 
Membership 235 
Four-fifths of publications indicated the number of committee members, . Publications giving details 236 
variedvarying from half (BMJ, 3/6) to 85% (HTA, 71/84). The number of members ranged from 2 to 52 with a 237 
median of 7. Details are provided in Table 6. 238 
 239 
110 publications listed members of which 84 specified a Chair. Other roles or fields of expertise were detailed 240 
in almost half of trials with a TSC (66/144). Common fields representerepresentationd were clinical (n=46), 241 
statistical (n=29) and patient and/or public (PPI) (n=39). 242 
 243 
Reporting was unclear with regards to membership and independence. 244 
 245 
Journal manuscripts 246 
One publication specified that the funder (NIHR) appointed the TSC, stating that members were ‘researchers 247 
independent of the study funders, although several have served on their advisory or funding committees’. 248 
[BMJ12]  249 
 250 
One publication indicated voting members when listing members [Lancet25].  251 
 252 
Ten NEJM publications gave details of TSC membership beyond listing members and affiliations. Half of these 253 
described sponsor representation, of whichwith one specifyingied this representation was as none voting 254 
[NEJM20].  255 
 256 
All 32 (9 Lancet, 23 NEJM) supplementary appendices reporting TSCs listed the members and/or affiliations.  257 
 258 
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Thirteen NEJM protocols discussed committee membership of the committee. Reporting in pProtocol 259 
reportings consisted listing members by role and/or field of expertise (n=10) or and by name (n=6), of which 260 
three reported both.  261 
 262 
Monographs 263 
46 monographs gave details of TSC membership beyond listing members and affiliations. 264 
 265 
Independence was discussed in 32 publications (32/46, 69.6%), of which 30 specified an independent Chair. Two 266 
reported funder input in selecting the chair.  267 
 268 
Members represented the following fields: clinical (n=12), PPI (n=6), statistical (n=3) and health economics (n=1). 269 
Including the chair, the number of independent memberss, discussed in 25 publications, ranged from two to six 270 
(and was most commonly three,  (n=17). Non-independent members, discussed in three publications, specified 271 
statistical (n=3) and health economics (n=2) representation. 272 
 273 
Thirty-one specified listed members without specifying independence. Represented fields were PPI (n=21), 274 
clinical (n=12), statistical (n=9), health economics (n=3) and funder (n=2). Three allowed observers at meetings. 275 
 276 
Meetings 277 
Journal manuscripts 278 
One publication discussed meeting frequency (bimonthly meetings [BMJ15]). No other papers detailed 279 
frequency. One publication stated yearly rtrial reports were circulated [Lancet3] possibly indicating yearly 280 
meetings.  281 
 282 
Seven supplementary protocols reported information related toprovided TSC meeting informations. Four 283 
reported gave the frequency of these, ranging from monthly to annually. Two were unclear were not specific 284 
e.g. statinged meetings were held periodically. Others reported that meetings were held by teleconference (n=2) 285 
and gave insight to report contents (n=1). 286 
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 287 
Monographs 288 
25 publications (25/144) discussed meeting frequency or timing. Of 22 specifying timings, tTimings, when 289 
specified, were biyearly (n=12); yearly (n=7); quarterly (n=2) and as required (n=1). Three publications gave 290 
meeting dates and another three gave the total number of meetings overall. One paper specified the length of 291 
TSC meetings as 80-100 minutes. Four papers indicated timing of first meeting as prior to (n=2) or at (n=1) trial 292 
commencement (n=1) and before recruitment (n=1).  293 
 294 
Role 295 
Journal manuscripts 296 
Eleven Lancet and 17 NEJM publications indicated role or responsibility. No BMJ articles discussed role. One 297 
supplementary appendix reporting TSCs (1/32, 1/23 NEJM) gave insight into TSC role.  298 
 299 
 300 
Design and oversight 301 
Four Lancet publications reported involvement in trialtrial design, specifically the committee designing the study 302 
with sponsor (2/4), designing the study under surveillance of the DMC (1/4) or supervising the design of the 303 
study (1/4). Eleven NEJM publications reported involvement in design, wherein the role encompassed 304 
overseeing (2/11), being responsible for (3/11) and/or involvement in (7/11) trial design, with , of which oone 305 
specifyinged this wasinvolvement independent of the sponsor.  306 
 307 
Three Lancet publications reported the TSC oversee the trial, of which one stated the TSC supervise operations. 308 
Of the nine NEJM publications discussing oversight and conduct, five specified stated the TSC oversee the trial 309 
(5/9), of which two required they oversee conduct specifically (2/9). A further four stated the TSC were 310 
responsible for study conduct (4/9). 311 
 312 
One supplementary appendix reporting TSCs (1/32, 1/9 Lancet) indicated operational oversight role, specifically:  313 
 “The Steering committee was responsible for overseeing the scientific and operational aspect of the 314 
study” [Lancet49] 315 
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 316 
Thirteen protocols discussed a role in oversight and relating to trial design: the reported TSC role encompassed 317 
monitoring (n=5) and oversight (n=5) of various aspects of the study (n=5). The TSC had a responsibility or 318 
participated in trial conduct (n=8) and design (n=5). One stated that the TSC was independent. 319 
 320 
Decision making 321 
Two Lancet articles publications reported the role of a decision making role, stating that the TSC could decide 322 
on study continuation. No Whilst no NEJM main papers reported the decision making as a role, however ninenine 323 
NEJM protocols did published as supplementary material did. Five protocols explicitly defined the TSC as the 324 
decision making body, the remaining four opted to provide examples of TSC decisions, such as altering sample 325 
size (n=2), patient withdrawals (n=1) and trial stopping (n=1).  326 
 327 
Contribution to trial documentation, data and analysis 328 
Seven Lancet publications reported TSC involvement in trial documentation, stating that the TSC wrote or 329 
contributed to the final report (3/7), made the decision to publish (2/7), or both (1/7). In one study tThe TSC 330 
coordinated and resolved doubts in interpretation in the protocol in another (1/7). Analysis and data 331 
involvement was reported in five studies, three of these stated the TSC had full access to data (3/5), one 332 
supervised the analysis (1/5) and three interpreted the results (one stating that this was done independently). 333 
Another stated: 334 
“The [TSC] vouched for the completion and accuracy of the data gathering and analysis.” [Lancet6] 335 
 336 
Seven NEJM publications reported TSC involvement in trial documentation, the committee contributedin 337 
contributing to writing the manuscript (4/7) and developeding the protocol (3/7), of which one developed the 338 
protocolthis with sponsor. Four papers reported TSC involvement in trial data, specifically the TSC had full access 339 
to data (1/4) and was involved with data collection (1/4); interpretation (1/4) and analysis (1/4). In seven, the 340 
committee made the decision to publish, one stated that the TSC vouches for integrity and completeness of the 341 
data and six stated:   342 
“The [TSC] vouches for the accuracy and completeness of the data and the analysis and the fidelity of 343 
the study to the protocol.” 344 
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 345 
One supplementary appendix reporting TSCs (1/32, 1/23 NEJM) gave insight into TSC role. Fifteen protocols 346 
discussed TSC input into trial documentation, data and analysis. The TSC was reported to have an input in 347 
publications (n=13), the protocol (n=7) and side studies (n=4).   348 
 349 
Communication 350 
No publications specified communication between TSC communicating withand other committees was not 351 
specified in any main publications. 352 
 353 
One appendix reporting TSCs (1/32) discussed communication, stating: 354 
“[the DMC] made recommendations to the Steering Committee regarding endpoint analysis or 355 
potential safety concerns” [Lancet49] 356 
 357 
Eight protocols discussed TSC communication with committeesng with: the DMC (n=7) and a Critical Event 358 
Committee (n=1). 359 
 360 
Monograph series 361 
40 monographs described TSC role. 362 
 363 
Design and oversight 364 
27 monographs described an oversight role, generally (11/27) or more specifically overseeing progress towards 365 
interim and overall objectives (8/27) or study progress of the study as a whole (8/27). Three stated independent 366 
this oversight was independent and two that his was on behalf of the trial sponsor. 367 
 368 
Generic definitions of TSC monitoring were provided in nine monographs. This was done in accordance with the 369 
MRC guidelines (n=6), Good Clinical Practice (n=1) and in two:  370 
“The [TSC] ensured that the rights, safety and well-being of the trial participants were the most 371 
important considerations and prevailed over the interests of science and society.” 372 
 373 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
14 
 
Decision making 374 
A decision making roleRole in decision making was reported in seven monographs. Examples were. Decisions 375 
about how the study is run (n=2); premature closing (n=5); and how pilot data and how it will inform the main 376 
trial (n=2) were listed. 377 
 378 
Trial documentation, data and analysis 379 
Twelve had the TSC review trial specific specific documentation. Specifically,  Specifically the statistical analysis 380 
plan (n=8) and the protocol (n=5).  381 
 382 
Ten stated the TSC review external information and five had authority over the publication strategy. One had 383 
the TSC approve further analysis and one approved additional studies.  384 
 385 
Communication 386 
The committee received recommendations from the DMC in six monographs, informed funders on trial progress 387 
in three, advised funders in one and liaised between the DMC and the Trial Management Group (TMG) in 388 
another. One stated TSC responsibility in resolving disputes between PIs and another had the DMC as a subgroup 389 
of the TSC. 390 
 391 
Activities 392 
Journal manuscripts 393 
TSC activity having impact on trial design, conduct and analysis was reported in 12 publications (3 BMJ; 7 Lancet; 394 
2 NEJM) with a total 14 examples reported (4 BMJ; 8 Lancet; 2 NEJM). No activities were reported in 395 
supplementary protocols. 396 
 397 
Design 398 
TIn twelve (12/14; 3/4 BMJ; 7/8 Lancet; 2/2 NEJM) publications reported TSC activity impacting trial design. 399 
Reported activities varied within journal. 400 
 401 
The BMJ reported TSC involvement changing the sample size (n=2) and primary outcome (n=1). 402 
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“Before the start of recruitment and data collection, we changed the primary outcome to the reported 403 
quit attempt measure, which is predictive of eventual cessation. This followed expert advice from the 404 
trial steering committee on the basis of smoking cessation research and approval from the data 405 
monitoring committee.” [BMJ15] 406 
 407 
All seven Lancet decisions regarded early stopping. In five, the TSC decided to stop recruitment, of which three 408 
reported that this decision was based on DMC recommendations. Others reported the TSC deciding to close 409 
recruitment to a trial arm (n=1) and make the decision to continue recruitment following an interim analysis 410 
(n=1).  411 
“Without revealing any results, the DSMB recommended to the executive committee and sponsor that 412 
the trial continue to the original pre-planned sample size. The basis for this recommendation was that, 413 
because of the rapid enrolment at the time of the interim analysis, there was insufficient 90 day data 414 
to assess the secondary endpoints, although there were no safety concerns. The executive committee 415 
and sponsor accepted the DSMB recommendation to continue enrolment, but remained masked to all 416 
study results.” [Lancet36] 417 
 418 
Within the NEJM publications reporting TSC activity relating to trial design (n=2), the committee established 419 
when patients could have their dose tapered [NEJM42] and when crossover could be permitted. 420 
“The independent data and safety monitoring committee and study steering committee concluded that 421 
both progression-free survival and overall survival were significantly longer in the trametinib group than 422 
in the chemotherapy group and that immediate crossover to trametinib should be permitted.” 423 
[NEJM23] 424 
  425 
One supplementary appendix reporting TSCs (1/32) published the letter of recommendation from the DMC to 426 
the TSC requesting one arm be closed due to accruing safety data [NEJM38], this was consistent with the main 427 
publication wherein the trial was prematurely stopped. 428 
 429 
Conduct 430 
No publication reporting TSC activity relating related to trial conduct.  431 
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 432 
Analysis 433 
Two (2/14; 1/4 BMJ; 1/8 Lancet) publications reported TSC activity impacting analysis.  434 
 435 
One described the TSC deciding to write a new SAP [BMJ3]. Another reported the TSC determining exclusions 436 
from analysis and imputations for deaths or drop outs [LANCET10].  437 
 438 
Monographs 439 
Thirty-seven monographs reported 60 examples of TSC activity. 440 
 441 
Design 442 
34 examples of TSC activity impacting trial design was reported in 23 monographs.  443 
 444 
Activities included the TSC changing the entry criteria (n=7); endpoints or outcomes (n=7); sample size (n=2); 445 
and randomisation ratio (n=1). Another reported the TSC closing a treatment arm (n=1). Others reported TSC 446 
impact in defining the study design (n=6) and recruitment period (n=2). 447 
 448 
Most significantly, the TSC made the decision to close the trial in five studies, as in HTA238;   449 
“In a meeting of the trial steering committee, it was accepted that it would not be viable to proceed 450 
with the trial and the formal procedure for closure (including notification of MHRA and MREC) was 451 
initiated in May 2005.” [HTA75] 452 
 453 
One monograph discussed the TSC overriding the recommendations of the DMC to close the trial; 454 
“Although the DMC recommended continuation of recruitment into FOOD following their meeting in 455 
2002, the Steering Committee took the decision to stop recruitment on 31 July 2003.” [HTA88] 456 
 457 
Conduct 458 
Fifteen examples of TSC activity impacting trial conduct was given in 14 monographs.  459 
 460 
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Examples of conduct were where the TSC: had input in determining the data collection process (4/14); 461 
considered consent issues (1/14) and input into safety issues, for example such as reviewing death data (1/14) 462 
and determining SAE data requirements (3/14). 463 
 464 
In three (3/14) the TSCs made the decision to changing treatment regimens, for example;  465 
"The project Steering Group determined that [a prescription] was inappropriate to a pragmatic study 466 
of this kind. It was agreed that the outcome would be more likely to represent the likely outcome of 467 
introducing TUVP if staff were to manage patients according to existing norms.” [HTA30] 468 
 469 
A further threeOthers (3/14) changed the recruitment procedure, for example:  470 
“On reflection and discussion of these issues, the research team and the trial steering committee 471 
members felt that some of these issues could have been addressed […]. They concluded that many of 472 
the problems encountered were a direct consequence of the changes in research governance and 473 
ethical procedures that prevent members of the research team approaching patients directly, but 474 
instead place the burden of recruiting patients on busy primary care professionals.” [HTA75] 475 
 476 
Analysis 477 
Ten examples of TSC activity impacting analysis was given in ten monographs.  478 
 479 
TSC impacted the analysis plan in seven monographs (7/10). Examples were: determining variables for 480 
regression model (2/7); defining equivalence limits (1/7), removing previously planned subgroup analyses (1/7), 481 
deciding on the analysis approach to be used e.g. intention-to-treat (2/7) or suggesting additional analysis.  482 
“Finally, at the request of the TSC, a further exploratory analysis to examine the interactive effect of 483 
age on the effectiveness of MRI compared with no MRI was conducted.” [HTA111] 484 
 485 
Other activities were the TSC determining protocol violations (1/10) and making the decision to unblind the trial 486 
team (2/10), for example: 487 
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“The identification of treatments was established by code break in the presence of the Chief 488 
Investigator, Trial Statistician and Trial Coordinator on 20 March 2007 by agreement with the TSC and 489 
DMEC.” [HTA104] 490 
 491 
DISCUSSION 492 
The extent of the adoption of a TSC, the committee with majority of independent members to whom the DMC 493 
make their recommendations, for trial oversight outside of the UK is unknown. Within the UK the establishment 494 
of a TSC is required by a number of major public funders yet, despite this, there is an absence of reporting 495 
standards regarding their constitution, activities and impact on clinical trial conduct.    496 
 497 
 498 
This paper aimed to provide the first review of reporting of TSC activity by looking atreviewing published 499 
literature generated from within and outside the UK.  Determining the role and contribution of this executive 500 
oversight committee was limited by a lack of reporting and, in particular, clear indication of whether this 501 
committee included a majority of, or even any, independent members.   It was often unclear whether the TSC 502 
being referenced was in fact the TSC or the TMG, the committee with heavy intellectual and practical investment 503 
in governing the day to day running of the trial. In trials where no major decisions need to be made, this may 504 
seem unimportant. In trials where DMC recommendations are not actioned then it is of increasing importance 505 
to understand the extent of the vested interests of the committee considering those recommendations. In the 506 
cohort reported here one such example was noted where the DMC recommended trial continuation but the TSC 507 
decided to close the trial. Arguably, this may be more concerning if this was the other way around, however, 508 
poor reporting standards will obscure this occurrence.  [HTA88] 509 
  510 
When interpreting these results, it is important to consider the limitations which include a restriction of the 511 
cohort to the top medical journals and the NIHR HTA monograph series. While this has the advantage publishing 512 
international trials, it may also be argued that these are of higher quality. The poor standards observed within 513 
this cohort therefore may be lower elsewhere. The time frame of this cohort also prevented consideration of 514 
changes over time, however, given the absence of attention received to this important role and its reporting 515 
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standards this is unlikely.  As previously discussed, the extent of the adoption of this oversight committee 516 
structure is not known for trials outside of UK and little is known about industry funded and sponsored trials.   517 
 518 
 519 
For TSCs to be accepted as good practice globally, then iit is important that the benefits and impact of such a 520 
committee are reported. This paper has highlighted the need to improve reporting of TSCs and in particular 521 
clarify the independence, or otherwise, of its members. Despite the literature search being conducted in 2012 522 
there has been no advancement in reporting guidelines in this area and the situation remains unchanged. 523 
Current reporting recommendations for DMCs [1, 2] could be used as a starting point with focus on decisions 524 
made by the TSC.   525 
 526 
One challenge of writing a report of a clinical trial is including pertinent information within word limits set by 527 
journals. It is often a balance of what can be left out without jeopardising quality. However, clarity of reporting 528 
on decision-making processes would seem essential given the potential for bias. With the availability of 529 
supplementary material, researchers must make this information publicly accessible. This would greatly aid the 530 
transparency of clinical trials and allow understanding of stakeholder involvement in decisions made.  531 
 532 
CONCLUSIONS 533 
This cohort examination provides the first examination of reporting practice of Trial Steering Committees 534 
involvement in randomised controlled trials. A lack of reporting standards has been identified, resultantly 535 
understanding the benefits and impact of the TSC role using the literature is challenging. Developing reporting 536 
guidelines is essential to aid determining the role and contribution of this executive oversight committee.  This 537 
would improve reporting standards, which would greatly aid the transparency of clinical trials and allow 538 
understanding of stakeholder involvement in decision making.  539 
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 582 
Figure 1: Flowchart of identification of eligible papers  583 
Uploaded separately - See Figure_1.docx 584 
Table 1: Trial demographics by journal 585 
Uploaded separately – See Table_1.docx 586 
The following details were extracted from eligible articles. 
 
SECTION 1: Trial details 
1.1. Title 
1.2. Authors 
1.3. Journal 
1.4. Funding body 
1.5. Year of publication (for HTA series only) 
1.6. Rationale of trial 
 
SECTION 2: Trial design 
2.1. Recruitment setting e.g. primary 
2.2. Type of trial e.g. parallel 
2.3. Number of trial arms 
2.4. Number of primary outcomes 
2.5. Type of primary outcome e.g. subjective 
2.6. Unit of randomisation 
2.7. Blinding 
i. Level of blinding 
ii. Reasons provided for non-blinding or level of blinding  
 
SECTION 3: Sample size 
3.1. What was the estimated sample size? 
3.2. Was the estimated sample size obtained? 
 
SECTION 4: Trial stopping 
4.1. Did the trial stop early? If yes, give details of why and how this decision was made 
 
SECTION 5: Oversight committee reporting 
5.1. If TSC reported 
i. Are the TSC members listed at the end of the paper? 
a. Name of committee 
b. Number of members 
c. Number of voting members 
d. Chair indicated 
e. Details regarding the number of members by role and by voting rights if applicable 
ii. Is the TSC discussed in the main body of the paper? If yes, give details. 
5.2. If DMC reported 
i. Are the DMC members listed at the end of the paper? 
a. Name of committee 
b. Number of members 
c. Number of voting members 
d. Chair indicated 
e. Details regarding the number of members by role and by voting rights if applicable 
ii. Is the DMC discussed in the main body of the paper? If yes, give details. 
5.3. If applicable, has the absence of committees been justified? If yes, give details. 
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Table 1: Trial demographics by journal 1 
   Journal 
(N in cohort) 
  
  
 
 BMJ 
(N=16) 
NEJM 
(N=55) 
Lancet  
(N=66) 
HTA 
(N=127) 
Total 
(N=264) 
  n n/N% n n/N% n n/N% n n/N% n n/N% 
Trial rationale Explanatory 0 0.0 0 0.0 5 7.6 2 1.6 7 2.7 
Pragmatic 6 37.5 2 3.6 10 15.2 88 69.3 106 40.2 
Not specified or clear 10 62.5 53 96.4 51 77.3 37 29.1 151 57.2 
Funder origin Asia 0 0.0 1 1.8 3 4.5 0 0.0 4 1.5 
     Japan 0 0.0 1 1.8 2 3.0 0 0.0 3 1.1 
     South Korea 0 0.0 0 0.0 1 1.5 0 0.0 1 0.4 
Australia 1 6.3 2 3.6 3 4.5 0 0.0 6 2.3 
     Australia 1 6.3 2 3.6 2 3.0 0 0.0 4 1.5 
     New Zealand 0 0.0 0 0.0 1 1.5 0 0.0 2 0.8 
Europe 14 87.5 21 38.2 40 60.6 127 100.0 202 76.5 
     Belgium 0 0.0 1 1.8 0 0.0 0 0.0 1 0.4 
     Denmark 3 18.8 2 3.6 0 0.0 0 0.0 5 1.9 
Table 1 Click here to download Table Table 1.docx 
   Journal 
(N in cohort) 
  
  
 
 BMJ 
(N=16) 
NEJM 
(N=55) 
Lancet  
(N=66) 
HTA 
(N=127) 
Total 
(N=264) 
  n n/N% n n/N% n n/N% n n/N% n n/N% 
     Finland 1 6.3 0 0.0 0 0.0 0 0.0 1 0.4 
     France 0 0.0 2 3.6 5 7.6 0 0.0 7 2.7 
     Germany 0 0.0 1 1.8 6 9.1 0 0.0 7  2.7 
     Ireland 1 6.3 0 0.0 2 3.0 0 0.0 3 1.1 
     Netherlands 2 12.5 1 1.8 2 3.0 0 0.0 5 1.9 
     Spain 0 0.0 0 0.0 1 1.5 0 0.0 1 0.4 
     Sweden 0 0.0 0 0.0 1 1.5 0 0.0 1 0.4 
     Switzerland 1 6.3 4 7.3 3 4.5 0 0.0 8 3.0 
     United Kingdom 6 37.5 9 16.4 19 28.8 127 100.0 161 61.0 
     Other (European Union) 0 0.0 1 1.8 1 1.5 0 0.0 2 0.8 
North America 1 6.3 30 54.5 20 30.3 0 0.0 51 19.3 
     Canada 0 0.0 1 1.8 0 0.0 0 0.0 1 0.4 
     United States of America 1 6.3 29 52.7 20 30.3 0 0.0 50 18.9 
Not specified 0 0.0 1 1.8 0 0.0 0 0.0 1 0.4 
   Journal 
(N in cohort) 
  
  
 
 BMJ 
(N=16) 
NEJM 
(N=55) 
Lancet  
(N=66) 
HTA 
(N=127) 
Total 
(N=264) 
  n n/N% n n/N% n n/N% n n/N% n n/N% 
Recruitment setting Primary 4 25.0 2 3.6 5 7.6 46 36.2 57 21.6 
Secondary only 2 12.5 2 3.6 5 7.6 17 13.4 26 9.8 
Tertiary only 3 18.8 17 30.9 30 45.5 47 37.0 97 36.7 
Secondary or tertiary (not specified) 0 0.0 0 0.0 2 3.0 3 2.4 5 1.9 
Community 7 43.8 4 7.3 2 3.0 15 11.8 28A 10.6 
Emergency 1 6.3 5 9.1 0 0.0 7 5.5 13 4.9 
Hospice 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 
Social care 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 
Other setting 0 0.0 1 1.8 1 1.5 0 0.0 2B 0.8 
Not clear 0 0.0 32 58.2 22 33.3 9 7.1 63C 23.9 
Trial design Parallel 13 81.3 48 87.3 59 89.4 103 81.1 233 88.3 
Sequential 0 0.0 1 1.8 1 1.5 1 0.8 3 1.1 
Crossover 0 0.0 1 1.8 2 3.0 5 3.9 9 3.4 
   Journal 
(N in cohort) 
  
  
 
 BMJ 
(N=16) 
NEJM 
(N=55) 
Lancet  
(N=66) 
HTA 
(N=127) 
Total 
(N=264) 
  n n/N% n n/N% n n/N% n n/N% n n/N% 
Cluster 2 12.5 0 0.0 2 3.0 11 8.7 15 5.7 
Factorial 1 6.3 5 9.1 2 3.0 7 5.5 15 5.7 
Number of trial arms 2 12 75.0 42 76.4 46 69.7 85 66.9 185 70.1 
3 3 18.8 7 12.7 10 15.2 29 22.8 49 18.6 
4 1 6.3 4 7.3 4 6.1 7 5.5 16 6.1 
5 0 0.0 2 3.6 2 3.0 5 3.9 9 3.4 
6 or more 0 0.0 0 0.0 4 6.1 1 0.8 5D 1.9 
Type of intervention E, F Pharmaceutical 3 18.8 41 74.5 54 81.8 34 26.8 132 50.0 
Cellular and gene therapy 0 0.0 1 1.8 2 3.0 0 0.0 3 1.1 
Medical device 0 0.0 5 9.1 5 7.6 16 12.6 26 9.8 
Surgery 0 0.0 3 5.5 1 1.5 10 7.9 14 5.3 
Radiotherapy 0 0.0 1 1.8 3 4.5 9 7.1 13 4.9 
Psychological and behavioural 6 37.5 0 0.0 1 1.5 22 17.3 29 11.0 
   Journal 
(N in cohort) 
  
  
 
 BMJ 
(N=16) 
NEJM 
(N=55) 
Lancet  
(N=66) 
HTA 
(N=127) 
Total 
(N=264) 
  n n/N% n n/N% n n/N% n n/N% n n/N% 
Physical 2 12.5 2 3.6 0 0.0 10 7.9 14 5.3 
Complimentary 0 0.0 0 0.0 1 1.5 5 3.9 6 2.3 
Resources and infrastructure  1 6.3 1 1.8 1 1.5 19 15.0 22 8.3 
Other 4 25.0 2 3.6 1 1.5 12 9.4 19 7.2 
Number of primary 
outcomes 
1 11 68.8 47 85.5 51 77.3 101 79.5 210 79.5 
2 2 12.5 3 5.5 10 15.2 13 10.2 28 10.6 
3 1 6.3 4 7.3 2 3.0 1 0.8 8 3.0 
4 or more 2 12.5 1 1.8 2 3.0 11 8.7 16 6.1 
Primary outcome type 
(Number of primary 
outcomes = 1) 
 N primary 
outcomes 
          
Subjective 1 3 18.8 0 0.0 2 3.0 39 30.7 44 16.7 
2+ 1 6.3 0 0.0 0 0.0 4 3.1 5 1.9 
Objective 1 6 37.5 46 83.6 46 69.7 53 41.7 151 57.2 
   Journal 
(N in cohort) 
  
  
 
 BMJ 
(N=16) 
NEJM 
(N=55) 
Lancet  
(N=66) 
HTA 
(N=127) 
Total 
(N=264) 
  n n/N% n n/N% n n/N% n n/N% n n/N% 
2+ 3 18.8 6 10.9 13 19.7 6 4.7 28 10.6 
Both 1 0 0.0 0 0.0 0 0.0 3 2.4 3G 1.1 
2+ 1 6.3 2 3.6 1 1.5 14 11.0 18 6.8 
Not clear 1 2 12.5 1 1.8 3 4.5 6 4.7 12 4.5 
2+ 0 0.0 0 0.0 1 1.5 2 1.6 3 1.1 
Allocation ratio Equal e.g. 1:1 13 81.3 46 83.6 55 83.3 115 90.6 229 86.7 
Not equal e.g. 2:1 2 12.5 8 14.5 10 15.2 12 9.4 32 12.1 
Not clear 1 6.3 1 1.8 1 1.5 0 0.0 3 1.1 
Unit of randomisation Individual 12 75.0 52 94.5 62 93.9 113 89.0 239 90.5 
GP practice 0 0.0 0 0.0 1 1.5 9 7.1 10 3.8 
Dyad (e.g. mother-child) 1 6.3 1 1.8 1 1.5 2 1.6 5 1.9 
Other 3 18.8 2 3.6 2 3.0 3 2.4 10H 3.8 
Blinding Yes, blinding 11 68.8 37 67.3 45 68.2 69 54.3 162 61.4 
   Journal 
(N in cohort) 
  
  
 
 BMJ 
(N=16) 
NEJM 
(N=55) 
Lancet  
(N=66) 
HTA 
(N=127) 
Total 
(N=264) 
  n n/N% n n/N% n n/N% n n/N% n n/N% 
No, not blinded Justification 
provided 
2 12.5 3 5.5 5 7.6 33 26.0 43I 
16.3 
Justification not 
provided 
1 6.3 9 16.4 15 22.7 10 7.9 35 
13.3 
Not clear 2 12.5 6 10.9 1 1.5 15 11.8 24 9.1 
A Advertisements in newsletters (n=1); Child and Adolescent Mental Health Services (n=1); Community mental health teams (n=1); Community nurse services (n=1); Community nursing 
services and community leg ulcers clinics (n=1); Community old age psychiatry services (n=1); Community sources (n=1); Department of Veterans affairs (n=3); National population registrar 
(n=1); Community paediatricians (n=1); Registrar (n=3); Schools (n=1); Secondary schools (n=1); University podiatry schools and podiatry clinics (n=1); Vaccination centres in schools (n=1); 
Villages (n=1); Not specified (n=8). 
 
B Other setting: Veteran Affairs Medical Centre (n=1); From other trials (n=1). 
 
C Not clear: Adult mental health setting (n=1); Antenatal clinic (n=1); Centres (n=29); Child and Adolescent Mental Health Services (n=1); Child development centre (n=1); Clinic site (n=1); 
Clinical centres (n=1); Clinical sites (n=1), Clinics (n=2); Countries (n=2); European medical centres (n=1); Institutes (n=1); Institutions (n=1); Sites (n=13); Not described (n=7). 
 
   Journal 
(N in cohort) 
  
  
 
 BMJ 
(N=16) 
NEJM 
(N=55) 
Lancet  
(N=66) 
HTA 
(N=127) 
Total 
(N=264) 
  n n/N% n n/N% n n/N% n n/N% n n/N% 
D Total arms equal to: six (n=2); eight (n=1); nine (n=1); twelve (n=1). 
 
E Defined by UK Clinical Research Collaboration Health Research Classification System 
 
F Categories not mutually exclusive 
 
G Both: Composite (n=3) [Disease improvement calculated from CHAQ, physician’ global assessment of disease activity, parents’ global assessment of overall well-being, number of joints with 
limited ROM, number of active joints and erythrocyte sedimentation rate. (n=1); Foot and ankle outcome score. (n=1); Post-operative nausea and vomiting (n=1). 
 
H Other units of randomisation: Clinic (n=1); Family (n=2); Hospital (n=1); Household (n=1); Partner (n=1); School (n=1); Village (n=1); Year group (n=1); Paediatric diabetes services (n=1). 
 
I Justification for no blinding: Not possible or practical due to nature of intervention or trial design (n=30); Not possible/practical as in practice caused difficulties for patients (n=1); Not 
possible/practical as shown by other similar trials (n=2); Not possible/practical so cluster randomisation approach used (n=1); Not possible – no additional justification given (n=4); Attempted 
to blind although were not successful (n=1); Large sample size means that results are not compromise (n=1); Not blinding reflects real practice (n=2); Test for impact of not blinding post trial 
(n=1). 
 2 
Table 2: Material reviewed by type and journal 
 
 Journal 
(N in cohort) 
  
Material BMJ 
(N=16) 
NEJM 
(N=55) 
Lancet  
(N=66) 
HTA 
(N=127) 
Total 
(N=264) 
n n/N% n n/N% n n/N% n n/N% n n/N% 
Main trial publication 16 100.0 55 100.0 66 100.0 127 100.0 264 100.0 
Study protocol as supplementary 
material 
0 0.0 50 90.9 0 0.0 NA . 50 18.9 
Other supplementary material excl. 
study protocol 
5 31.3 52 94.5 50 75.8 NA . 107 40.5 
Table 2 Click here to download Table Table 2.docx 
Table 3: Level of TSC and DMC reporting split by journal 
 Journal 
(N in cohort) 
 
Committee(s) reported BMJ 
(N=16) 
NEJM 
(N=55) 
Lancet 
(N=66) 
HTA 
(N=127) 
Total 
(N=264) 
TSC and DMC reported  
 
N papers reporting TSC (DMC) 
- Acknowledged / listed 
- Main paper TSC 
- Supplementary paper 
- Protocol 
4 
25.0% 
 
2 (2) 
2 (2) 
0 (0) 
0 (0) 
31 
56.4% 
 
19 (23) 
7 (6) 
0 (0) 
5 (2) 
19 
28.8% 
 
14 (15) 
5 (4) 
0 (0) 
0 (0) 
55 
43.3% 
 
52 (50) 
3 (5) 
NA 
NA 
109 
41.3% 
 
87 (90) 
17 (17) 
0 (0) 
5 (2) 
TSC only reported 
 
N papers reporting TSC 
- Acknowledged / listed 
- Main paper TSC (DMC) 
- Supplementary paper 
- Protocol 
- Reason for no DMC provided 
2 
12.5% 
 
1 
1 
0 
0 
0 
3 
5.5% 
 
2 
1 
0 
0 
0 
1 
1.5% 
 
1 
0 
0 
0 
0 
29 
22.8% 
 
19 
10 
NA 
NA 
3 
35 
13.3% 
 
23 
12 
0 
0 
3 
DMC only reported 
 
N papers reporting DMC 
- Acknowledged / listed 
- Main paper TSC (DMC) 
- Supplementary paper 
- Protocol 
- Reason for no TSC provided 
0 
0.0% 
 
0 
0 
0 
0 
17 
30.9% 
 
8 
6 
1 
2 
26 
39.4 
 
3 
22 
1 
0 
6 
4.7% 
 
5 
1 
NA 
NA 
49 
18.6% 
 
16 
29 
2 
2 
Table 3 Click here to download Table Table 3.docx 
 0 0 0 0 0 
Neither committee reported 
 
N papers 
- Reason for no TSC provided 
- Reason for no DMC provided 
10 
62.5% 
 
0 
0 
4 
7.3% 
 
0 
2 
20 
30.3% 
 
0 
0 
37 
29.1% 
 
0 
0 
71 
26.9% 
 
0 
2 
Table 4a: Oversight committee split by intervention type 
Intervention type 
TSC reported DMC reported 
Yes No Yes No 
  N N n/N% N n/N% n n/N% N n/N% 
Pharmaceutical 132 68 51.5% 64 48.5% 97 73.5% 35 26.5% 
Cellular and gene therapy 3 0 0.0% 3 100.0% 2 66.7% 1 33.3% 
Medical device 26 17 65.4% 9 34.6% 19 73.1% 7 26.9% 
Surgery 14 9 64.3% 5 35.7% 9 64.3% 5 35.7% 
Radiotherapy 13 7 53.8% 6 46.2% 5 38.5% 8 61.5% 
Psychological and behavioural 29 14 48.3% 15 51.7% 11 37.9% 18 62.1% 
Physical 14 11 78.6% 3 21.4% 8 57.1% 6 42.9% 
Complimentary 6 3 50.0% 3 50.0% 2 33.3% 4 66.7% 
Resources and infrastructure  22 13 59.1% 9 40.9% 5 22.7% 17 77.3% 
Other 19 13 68.4% 6 31.6% 7 36.8% 12 63.2% 
 
Table 4a Click here to download Table Table 4a.docx 
Table 4b: Oversight committee split by intervention type 
Intervention type 
Committee(s) reported 
TSC and DMC 
TSC and no 
DMC 
DMC and no TSC 
No TSC and no 
DMC 
  N n n/N% n n/N% n n/N% n n/N% 
Pharmaceutical 132 60 45.5% 8 6.1% 37 28.0% 27 20.5% 
Cellular and gene therapy 3 0 0.0% 0 0.0% 2 66.7% 1 33.3% 
Medical device 26 16 61.5% 1 3.8% 3 11.5% 6 23.1% 
Surgery 14 6 42.9% 3 21.4% 3 21.4% 2 14.3% 
Radiotherapy 13 4 30.8% 3 23.1% 1 7.7% 5 38.5% 
Psychological and behavioural 29 9 31.0% 5 17.2% 2 6.9% 13 44.8% 
Physical 14 7 50.0% 4 28.6% 1 7.1% 2 14.3% 
Complimentary 6 2 33.3% 1 16.7% 0 0.0% 3 50.0% 
Resources and infrastructure  22 4 18.2% 9 40.9% 1 4.5% 8 36.4% 
Other 19 7 36.8% 6 31.6% 0 0.0% 6 31.6% 
 
Table 4b Click here to download Table Table 4b.docx 
Table 5: TSC name split by journal 
Name of TSC 
Journal 
(N reporting TSC) 
Total 
(N=144) 
BMJ 
(N=6) 
NEJM 
(N=34) 
Lancet  
(N=20) 
HTA 
(N=84) 
n n/N% N n/N% n n/N% n n/N% n n/N% 
Trial Steering Committee 6 100.0 1 2.9 6 30.0 48 57.1 61 41.7 
Steering Committee 0 0.0 18 52.9 12 60.0 12 14.3 42 29.2 
Steering Group 0 0.0 0 0.0 0 0.0 14 16.7 14 9.7 
Executive Committee 0 0.0 9 26.5 1 5.0 0 0.0 10 6.9 
Trial Steering Group 0 0.0 0 0.0 0 0.0 4 4.9 4 2.8 
Advisory Committee 0 0.0 2 5.9 0 0.0 0 0.0 2 1.4 
Project Steering Group 0 0.0 0 0.0 0 0.0 2 2.4 2 1.4 
Study Steering Committee 0 0.0 1 2.9 0 0.0 1 1.2 2 1.4 
Clinical Research Organization 0 0.0 1 2.9 0 0.0 0 0.0 1 0.7 
External Protocol Advisory Committee 0 0.0 1 2.9 0 0.0 0 0.0 1 0.7 
Monitoring and steering committee 0 0.0 1 2.9 0 0.0 0 0.0 1 0.7 
Neurology Steering Committee 0 0.0 0 0.0 1 5.0 0 0.0 1 0.7 
Scientific Advisory Group 0 0.0 0 0.0 0 0.0 1 1.2 1 0.7 
Steering and Advisory Group 0 0.0 0 0.0 0 0.0 1 1.2 1 0.7 
Trial Advisory Group 0 0.0 0 0.0 0 0.0 1 1.2 1 0.7 
Note: Tabled sorted by total column. 
 
Table 5 Click here to download Table Table 5.docx 
Table 6: Membership details provided split by journal 
   Journal 
(N reporting TSC) 
 
   BMJ 
(N=6) 
NEJM 
(N=34) 
Lancet 
(N=20) 
HTA 
(N=84) 
Total 
(N=144) 
Number of members 
 
n (n/N%) 
mean (sd) 
median (IQR) 
(min, max) 
3 (50.0) 
5 (2) 
5 (3) 
(4, 7) 
20 (58.8) 
13 (12) 
9 (9) 
(4, 52) 
16 (80.0) 
8 (5) 
6 (5) 
(3, 22) 
71 (84.5) 
8 (6) 
6 (5) 
(2, 34) 
110 (77) 
9 (7) 
7 (6) 
(2, 52) 
Chair indicated n (n/N%) 3 (50.0) 20 (58.8) 9 (45.0) 52 (61.9) 84 (58.3) 
Expertise of members indicated n (n/N %) 1 (16.7) 10 (29.4) 4 (20.0) 51 (60.7) 66 (45.8) 
Expertise Chief investigator n (n/N%) 0 (0.0) 9 (26.5) 2 (10.0) 13 (15.5) 24 (16.7) 
Trial coordinator n (n/N%) 0 (0.0) 1 (2.9) 0 (0.0) 5 (6.0) 6 (4.2) 
Clinical expert n (n/N%) 0 (0.0) 3 (8.8) 2 (10.0) 41 (48.8) 46 (31.9) 
Statistician n (n/N%) 0 (0.0) 4 (11.8) 2 (10.0) 23 (27.4) 29 (20.1) 
PPI representative n (n/N%) 1 (16.7) 2 (5.9) 0 (0.0) 36 (42.9) 39 (27.1) 
Health economist n (n/N%) 0 (0.0) 0 (0.0) 0 (0.0) 11 (13.1) 11 (7.6) 
Sponsor representative n (n/N%) 0 (0.0) 5 (14.7) 1 (5.0) 2 (2.4) 8 (5.6) 
Industry representative n (n/N%) 0 (0.0) 1 (2.9) 0 (0.0) 1 (1.2) 2 (1.4) 
 
Table 6 Click here to download Table Table 6.docx 
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